Axcan Pharma Inc. ("Axcan" or "the Company") (TSX:

Axcan Pharma Inc. ("Axcan" or the "Company") (TSX: AXP)(NASDAQ: AXCA) today announced that in light of the previously-announced pending acquisition of Axcan by an affiliate of TPG Capital, the Company wishes to disclose currently available financial information for its first quarter of fiscal 2008.

Axcan Pharma Inc. ("Axcan") (TSX: AXP)(NASDAQ: AXC

Axcan Pharma Inc. ("Axcan" or the "Company")-(TSX:

SOPHIA ANTIPOLIS, France, May 11 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today provided an update on the phase 2a study for NCX 1000, which is covered by its codevelopment agreement with Axcan Pharma Inc. (Nasdaq: AXCA; TSX: AXP).